Targeting JunD: a potential strategy to counteract hormone-refractory prostate cancer.

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

Who cites it

5 citing papers in PubMed.

1. JUNB and JUND in Urological Cancers: A Literature Review.Current issues in molecular biology · 2025
   Review
2. Menin-MLL1 Interaction Small Molecule Inhibitors: A Potential Therapeutic Strategy for Leukemia and Cancers.Molecules (Basel, Switzerland) · 2023
   Review
3. Tead and AP1 Coordinate Transcription and Motility.Cell reports · 2016
   Article
4. Molecular signatures in the prevention of radiation damage by the synergistic effect of N-acetyl cysteine and qingre liyan decoction, a traditional chinese medicine, using a 3-dimensional cell culture model of oral mucositis.Evidence-based complementary and alternative medicine : eCAM · 2015
   Article
5. ellipsoidFN: a tool for identifying a heterogeneous set of cancer biomarkers based on gene expressions.Nucleic acids research · 2013
   Article

Corrections and comments

• Comment on
  JunD-mediated repression of GADD45α and γ regulates escape from cell death in prostate cancer.2011

Authors and funding

3 authors.

Funding

Abstract

PubMed holds no abstract for this paper.

Indexed as